Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

2018 ◽  
Vol 5 (1) ◽  
pp. e23-e34 ◽  
Author(s):  
Chloe Orkin ◽  
Jean-Michel Molina ◽  
Eugenia Negredo ◽  
José R Arribas ◽  
Joseph Gathe ◽  
...  
Keyword(s):  
Protease Inhibitors ◽  
Tenofovir Disoproxil Fumarate ◽  
Efficacy And Safety ◽  
Phase 3 ◽  
Tenofovir Alafenamide ◽  
Hiv 1

scholarly journals Using a single tablet regimen of darunavir, cobicistat, emcitrabine, and tenofovir alafenamide in virally suppressed HIV-1 patients is an adequate treatment option for controlling HIV

2021 ◽  
Vol 7 (2) ◽  
Author(s):  
Priya Kathuria
Keyword(s):  
Protease Inhibitors ◽  
Treatment Option ◽  
Tenofovir Disoproxil Fumarate ◽  
Clinical Decision ◽  
Efficacy And Safety ◽  
Phase 3 ◽  
Adequate Treatment ◽  
Single Tablet Regimen ◽  
Tenofovir Alafenamide ◽  
Hiv 1

A clinical decision report using: Orkin C, Molina JM, Negredo E, et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 2018;5(1):e23-e34. https://doi.org/10.1016/S2352-3018(17)30179-0 for a patient with viriologically suppressed HIV-1.

Sign in / Sign up

Export Citation Format

Share Document